首页>
外国专利>
A METHOD OF PREDICTING RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA PATIENTS
A METHOD OF PREDICTING RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA PATIENTS
展开▼
机译:一种预测多发性骨髓瘤患者对沙利度反应的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method of predicting response to thalidomide, or thalidomide analogs, in an individual with cancer, especially cancers for which thalidomide has been implicated as a treatment, such as Multiple Myeloma (MM) employs one or more of a panel of biomarkers that have been shown to be differentially expressed in cancer patients that respond to thalidomide (hereafter "Responders") relative to cancer patients that do not respond to thalidomide (hereafter "Non-responders). The method involves assaying a biological sample from the individual to determine the abundance of at least three biomarkers including Vitamin-D binding protein precursor(VDB) (Sequence ID 1) and Serum amyloid A protein (SAA) (Sequence ID 3), and at least one of beta-2-microglobulin (B2M) (Sequence ID 4), Haptoglobin (Hp) precursor (fragment) (Sequence ID 5), and zinc-alpha-2- glycoprotein (ZAG) (Sequence ID 2). Correlation of the abundance value for the at least three biomarkers with a reference abundance value from a Responder or Non-responder enables predication of response to thalidomide for the patient.
展开▼